La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kyverna Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kyverna Therapeutics..

Kyverna Therapeutics (NASDAQ:KYTX) Azioni, Catena delle Opzioni

Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

KYTX

PSFE

RMBL

I titoli da tenere d&#39;occhio oggi: Home Depot, RumbleOn, Paysafe, Kyverna Therapeutics e XP Inc. nel pre-market.

Pre-market: 5 titoli da monitorare oggi, 13 agosto 2024

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics Inc

Morgan Stanley analyst Mike Cyprys maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and lowers the price target from $1275 to $1124.

Price Target

Analyst Ratings

Morgan Stanley Maintains Overweight on BlackRock, Lowers Price Target to $1124

The Board of PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) ("PureTech" or the "Company") notes the recent press speculation and confirms that it is in discussions with Nordic Capital Epsilon SCA, SICAV-RAIF (acting through its general partner Nordic Capital Epsilon GP SARL) ("Nordic Capital") regarding a possible cash offer to acquire the entire share capital of the Company.
A further announcement will be made as and when appropriate. There can be no certainty that any firm offer will be made for the Company, nor as to the terms on which any firm offer might be made.
In accordance with Rule 2.6(a) of the Code, Nordic Capital is required, by no later than 5.00 p.m. (London time) on 5 May 2025, being 28 days after the date of this announcement, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code.
The person responsible for arranging release of this announcement on behalf of PureTech is Charles Sherwood, General Counsel.
This announcement is being made without the consent of Nordic Capital.

Contracts

Asset Sales

PRTC

PureTech Health Confirms Ongoing Discussions With Nordic Capital Regarding Possible Cash Offer For Entire Share Capital, With A Decision Expected By May 5, 2025

Morgan Stanley analyst Michael Cyprys maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and lowers the price target from $18 to $15.

Morgan Stanley Maintains Underweight on Franklin Resources, Lowers Price Target to $15

Morgan Stanley analyst Rayna Kumar upgrades SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) from Underweight to Overweight and lowers the price target from $81 to $77.

Upgrades

SEIC

Morgan Stanley Upgrades SEI Inv to Overweight, Lowers Price Target to $77

JNVR

Janover Shares Resume Trade

Morgan Stanley analyst Ryan Kenny maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Underweight and lowers the price target from $70 to $42.

Morgan Stanley Maintains Underweight on Moelis, Lowers Price Target to $42

A false report claiming the Trump administration was preparing a <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">90-day pause on tariffs</a> triggered a wave of volatility across U.S. equity and crypto markets on Monday.
What Happened: The confusion began when an unverified post on X suggesting a temporary tariff halt made its way to CNBC's headline feed without confirmation.
The headline was later picked up by Reuters, further amplifying the misleading report. 
The White House quickly denied the claim, telling CNBC that no such policy was under consideration and labeling the headlines as "fake news."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44664914/bitcoin-ethereum-xrp-dogecoin-obliterate-142-billion-in-liquidations-plummet-up-to-16">Bitcoin, Ethereum, XRP, Dogecoin Obliterate $1.42 Billion In Liquidations, Plummet Up To 16%</a>
Why It Matters: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) saw a sharp swing, rising above $520 at the open before tumbling below $495 shortly after the rumor was debunked.
The index's swing represented an approximate $2 trillion loss in market value, highlighting the fragility of investor sentiment amid ongoing trade policy tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), too, responded sharply to the fake headline. 
The cryptocurrency surged from $77,500 to $80,800 within minutes as hopes of a tariff pause spread. 
But once the rumor was invalidated, BTC corrected back to around $78,000, giving up most of its gains.
Nasdaq futures were also caught in the turmoil, swinging in double-digit percentage ranges. 
Analysts attributed the erratic price action to a mix of headline-driven algorithmic trading and heightened market sensitivity to geopolitical and economic policy headlines.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44657151/ripple-warns-this-country-is-falling-behind-in-the-crypto-race">Ripple Warns: This Country Is Falling Behind In The Crypto Race</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Whipsaws As Trillions In Market Value Are Erased On Fake Tariff Pause Rumor

CLIK

Click Shares Resume Trade Following Circuit Breaker Halt

"Market reverses on volatility after White House reportedly alleges '90-day tariff pause' headline circulated by notable X accounts is 'fake news'"
 &nbsp;

WIIM

SUNE

SUNation Energy shares are trading lower. The company announced it closed the final tranche of its registered direct offering.

Morgan Stanley analyst Ryan Kenny maintains Houlihan Lokey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLI#NYSE">HLI</a>) with a Overweight and lowers the price target from $190 to $156.

Morgan Stanley Maintains Overweight on Houlihan Lokey, Lowers Price Target to $156

EQNR

SHEL

Shares of energy stocks are trading lower as crude oil falls to 2021 levels, following OPEC+'s decision to accelerate production hikes. The market is also grappling with fears of a recession, fueled by President Trump's recent tariff announcements and China's retaliatory measures, which have heightened concerns over global demand.

Morgan Stanley analyst Ryan Kenny downgrades Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Equal-Weight to Underweight and lowers the price target from $56 to $33.

Downgrades

Morgan Stanley Downgrades Lazard to Underweight, Lowers Price Target to $33

Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is giving investors some good news — especially if they're keeping a close eye on its <a href="https://www.benzinga.com/quote/VRTX/news">newly launched painkiller Journavx</a>.
<h1 class="wp-block-heading">Journavx Gains Early Traction</h1>
At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor Relations Susie Lisa.
The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U.S. pharmacy shelves.
Coverage is picking up faster than anticipated, and while the drug is mostly placed in Tier 3 for now, management downplayed the concern. "It's all about overall value," they emphasized, as anecdotal reports suggest that both prescribing physicians and patients are seeing encouraging results.
Read Also: <a href="https://www.benzinga.com/insights/short-sellers/25/04/44591879/is-vertex-pharmaceuticals-gaining-or-losing-market-support">Is Vertex Pharmaceuticals Gaining or Losing Market Support?</a>
<h1 class="wp-block-heading">Two Levers To Watch In 2025</h1>
Fye highlighted that Vertex&#8217;s 2025 revenue guide of $11.75 billion to $12 billion is primarily powered by cystic fibrosis therapies, but she also noted "two potential upside levers" to that figure: 
<ul>
<li>A quicker-than-expected ramp-up for Journavx</li>
<li>Faster patient dosing for gene-editing therapy Casgevy.</li>
</ul>
The former is shaping up nicely already, while the latter, she noted, remains "a long journey."
<h1 class="wp-block-heading">Alyftrek and International Challenges</h1>
The company remains confident in Alyftrek, its next-gen cystic fibrosis drug with once-daily dosing and an expanded mutation profile.
There is, however, one international wrinkle: the expected revenue drag from Russia's disregard of Vertex's intellectual property rights. 
Still, with a high-quality profile and positive momentum in pain and gene therapy, Fye believes Vertex could continue to benefit from rotation in this macro backdrop.
JPMorgan reiterated its Overweight rating.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44652995/vertex-alnylam-best-positioned-as-biopharma-braces-for-tariff-impact-goldman-sachs-analyst-flags-regeneron-biogen-risks">Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks</a></li>
</ul>
Photo: Shutterstock

Biotech

Long Ideas

Health Care

General

VRTX

Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'

Janover Shares Resume Trade Then Again Halt On Circuit Breaker To The Downside, Stock Now Up 498%

Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, showing continued clinically and meaningful benefit for early <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">Alzheimer&#8217;s disease patients</a>.
ATTENTION-AD (ANAVEX 2-73-AD-EP-004) trial result was presented at the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44656765/anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase-iibiii-" rel="noreferrer noopener">AD/PDTM&nbsp;2025 Conference</a>.
Continued blarcamesine treatment for up to four (4) years demonstrated a good comparative safety profile and no associated neuroimaging adverse events (no potentially fatal brain bleeding or brain swelling).
There were no deaths related to the study drug.
Blarcamesine-treated patients continue to accrue benefit through 4 years, as measured by the clinical endpoints ADAS-Cog13 and ADCS-ADL.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40009941/neurodegenerative-disease-focused-anavex-life-sciences-alzheimers-candidate-slows-disease-progres" rel="noreferrer noopener">Neurodegenerative Disease-Focused Anavex Life Sciences&#8217; Alzheimer&#8217;s Candidate Slows Disease Progression By Almost 39%</a>
The delayed-start analysis for ADAS-Cog13 (assess cognitive function) showed a significant difference between the early start and late start treatment groups up to Week 192 (LS mean difference -3.83, P = 0.0165), favoring the early start group.
The results suggest that participants who initiated treatment with blarcamesine earlier in their disease progression showed greater cognitive function stability than those who did not initiate blarcamesine until ~1 year later.
In addition, an ADAS-Cog13 score difference between the treatment groups at Week 192 of more than 2 points is considered a clinically meaningful improvement.
Similarly, the delayed-start analysis for ADCS-ADL (functional evaluation scale) showed numerically favorable results for the early-start group over the late-start group up to Week 192. It reached statistical significance (LS mean difference +4.30, P = 0.0206).
With few or no interrupted treatment days, blarcamesine treatment resulted in an improved treatment effect for both cognition, ADAS-Cog13 (LS mean difference -4.20, P = 0.0083), and function, ADCS-ADL (LS mean difference +5.75, P = 0.0015) at Week 192.
Blarcamesine exhibited a favorable safety profile with the majority of adverse events (AEs) mild to moderate in severity (Grade 1 or 2), were predominantly linked to the initial titration phase, and could be managed with adjusted titration schedules.
Lastly, there are currently 74 participants receiving blarcamesine within the Compassionate Use Program, who continued treatment with blarcamesine subsequent completion of respective preceding open-label-extension studies from both ANAVEX 2-73-AD-EP-004 in early AD and from ANAVEX2-73-003 in mild-to-moderate AD.
Price Action: AVXL stock is down 1.71% at $8.05 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44651990/arvinas-touts-positive-data-from-potential-parkinsons-candidate-in-human-study-with-healthy-volunteers" target="_blank" rel="noreferrer noopener">Arvinas Potential Parkinson&#8217;s Treatment Shows Positive Data In Human Study</a></li>
</ul>
Photo by Berit Kessler via Shutterstock

AVXL

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years

Morgan Stanley analyst Ryan Kenny downgrades Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) from Overweight to Equal-Weight and lowers the price target from $306 to $173.

Morgan Stanley Downgrades Evercore to Equal-Weight, Lowers Price Target to $173

<a href="https://news.vrtx.com/news-releases/news-release-details/european-commission-approves-expanded-label-kaftrior-combination" title="https://news.vrtx.com/news-releases/news-release-details/european-commission-approves-expanded-label-kaftrior-combination">https://news.vrtx.com/news-releases/news-release-details/european-commission-approves-expanded-label-kaftrior-combination</a>

Global

'European Commission Approves Expanded Label For KAFTRIO In Combination With Ivacaftor For People With Cystic Fibrosis'

AAPL

Apple shares are trading lower after Wedbush cut its price target on the stock from $325 to $250.

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) plunged to $1.65 on Monday, its lowest price since November of last year, as investors fled crypto markets amid escalating global trade tensions sparked by U.S. <a href="https://www.benzinga.com/markets/equities/25/04/44628003/the-big-liberation-day-surprise">President Donald Trump's newly imposed tariffs</a>.
The <a href="https://www.benzinga.com/markets/options/25/04/44636496/why-tsem-stock-bounce-back-liberation-day-panic">so-called "Liberation Day" tariffs</a>, issued April 2, introduced sweeping duties on imports from China, Canada, and Mexico—including a 20% tax on Chinese goods and 25% on steel and aluminum. The policy has rattled global financial markets and triggered a sharp risk-off response from investors, sending major cryptocurrencies, including XRP, into a steep correction.
XRP has lost nearly 25% of its value in the past month, dropping 12.3% on Monday alone after a 10.4% plunge Sunday. At the time of writing, the coin is trading at $1.79 with a market capitalization of $103.48 billion. According to Coinglass, $71.28 million in XRP bullish positions were liquidated in the last 24 hours, which points to the scale of investor capitulation.
Why Is XRP Falling?
The answer lies in both macroeconomic and technical factors. Cryptocurrencies are inherently risk assets, meaning they typically decline when investor sentiment turns defensive. Trump's aggressive trade policy has triggered fears of a global economic slowdown and rising inflation—conditions historically unfavorable for digital assets.
"Since trade war worries began on January 20th, crypto markets have erased -$800 BILLION," The Kobeissi Letter, an industry commentator, warned on X.&nbsp;
Broader market dynamics have only added pressure. Bitcoin fell below $78,000 while Ethereum tumbled below $1,500 before slightly rebounding. XRP, which maintains a strong correlation with Bitcoin, has followed suit.
Technically, XRP has breached the critical $2.00–$2.01 support level, which had held since December. The move completes a bearish head-and-shoulders formation, with additional downside risk if XRP closes below the $1.77 trendline. Should the support fail, technical indicators warn of a possible drop to $1.50—or even $1.00.
XRP Price Predictions for April 7, 2025
<div class="bz-widget" data-name="xrp-price-prediction-table"></div>
What's Next for XRP?
Despite the current turmoil, analysts remain cautiously optimistic about XRP's long-term outlook. Changelly forecasts an average price of $3.13 by the end of 2025, while Bitwise calls for the coin to reach $3.90 by the end of this year.
Investors should monitor the $1.70 support zone and brace for continued volatility as global macro pressures ripple across crypto markets.

$XRP

Why Is XRP Down Today? Trump's Trade War Triggers Sell-Off As Price Hits Five-Month Low

Bitcoin (BTC) plunged to as low as $74,804 on Monday, marking its lowest level in months and igniting fresh concern across crypto markets.&nbsp;
The sudden drop followed <a href="https://www.benzinga.com/markets/equities/25/04/44628003/the-big-liberation-day-surprise">President Donald Trump's sweeping tariff announcement</a>, which has reignited fears of a global recession and triggered a sharp sell-off in risk assets—including cryptocurrencies.
As of this writing, Bitcoin is trading at $76,577.05, down nearly 9.5% in 24 hours, and nearly 30% off its January all-time high near $110,000.
Trump's Tariffs Trigger a Risk-Off Avalanche
The catalyst for the crash is clear. <a href="https://www.benzinga.com/markets/options/25/04/44636496/why-tsem-stock-bounce-back-liberation-day-panic">Trump's "Liberation Day" tariffs</a>, which imposed a blanket 10% import tax on foreign goods and targeted levies of up to 54% on imports from China and India. The move spooked global markets, sending equity indexes tumbling worldwide and wiping out trillions in value.
Bitcoin, often treated as a proxy for risk-on sentiment, was caught in the crossfire. According to Coinglass, more than $411 million in Bitcoin long positions were liquidated in the past 24 hours, underscoring the severity of the market's move.
"The window of uncertainty has only widened for markets over the last few weeks, and Bitcoin is not immune when people need to sell what they can for posting margin or internal risk models," said independent crypto analyst Will Clemente in a statement to CNBC.
The 1987 Black Monday Comparison
The panic, according to market commentator Jim Cramer, resembles the conditions surrounding 1987's Black Monday, when the Dow Jones Industrial Average fell 22.6% in a single day. On Monday, the VIX index—Wall Street's volatility gauge—surged past 50, its highest reading since 2020, signaling acute investor anxiety.
An analysis from 99Bitcoins drew parallels to Black Monday's rapid collapse, highlighting that global equity markets have dropped 7% to 13% in just a few sessions. The report pointed to Bitcoin's role as a speculative asset, still vulnerable to broader market sentiment despite growing institutional adoption.
Bitcoin Technical Levels to Watch
From a technical standpoint, Bitcoin's break below $78,000 and now $75,000 places it in an interesting position. The breach invalidated a recent consolidation range and appears to confirm a bearish trend continuation.
Analysts are eyeing $70,000 as the next critical support level, with $68,000—the February low—representing a longer-term floor. Should those levels fail, some traders fear a drop toward $60,000, where Bitcoin last consolidated in late 2024.
Conversely, a recovery above $80,000, which has acted as psychological resistance, could help restore bullish momentum.
What Analysts Are Saying
Despite the recent downturn, some analysts maintain a long-term bullish outlook on Bitcoin, particularly amid macroeconomic instability and deglobalization trends.
Standard Chartered's Head of Digital Assets, Geoff Kendrick, noted on Sunday that Bitcoin "will become a hedge against tariff risks this time around," suggesting the digital asset could benefit from mounting skepticism toward fiat currencies.
Clemente echoed the sentiment. "Should equities get relief, bitcoin will likely follow as well."
The Outlook: Caution, Not Capitulation
While the weekend sell-off was severe, there are signs that the correction may be nearing exhaustion—provided no further macro shocks materialize. Bitcoin remains one of the best-performing assets over the past 12 months, even after accounting for this latest drawdown.
Still, the outlook remains uncertain. With global equity markets under pressure, interest rates elevated, and crypto-specific catalysts on pause, Bitcoin's path forward depends heavily on macro sentiment.
Bitcoin Price Prediction for April 8, 2025
<div class="bz-widget" data-name="btc-price-prediction-table"></div>
As always, investors are advised to watch key support levels, manage risk appropriately, and monitor geopolitical developments closely. While Bitcoin may ultimately prove resilient, the days ahead are likely to remain turbulent.

Why Is Bitcoin Down Today? Trump Tariffs Spark Market Panic as BTC Slides Below $75K

Press Releases

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Legal

Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Comments

Kyverna Therapeutics

Kyverna Therapeutics (KYTX) Opzioni

Kyverna Therapeutics (NASDAQ:KYTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO